Celator Pharmaceuticals Enrolls First Patient in Its Phase 3 Study of CPX-351 in Untreated High-Risk Acute Myeloid Leukemia

Celator Pharmaceuticals announced that the first patient has been treated in its Phase 3, multicenter, randomized, open-label clinical trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus conventional cytarabine and daunorubicin therapy (“7+3”) as first-line therapy in patients 60-75 years old with high-risk (secondary) acute myeloid leukemia (AML).
Fort Mill Times